The Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, signed a Memorandum of Understanding with Roche Products (India) Pvt. Ltd. to bolster DPIIT-recognized startups working in critical therapeutic areas such as oncology, neurology, ophthalmology, haematology, and rare diseases. Under the MoU, Roche India will provide mentorship from global experts, support pilot and validation studies, and offer access to cutting-edge technologies, infrastructure, and international platforms to help scale promising innovations.
The MoU was formally signed by Director, DPIIT, Dr. Sumeet Jarangal and Managing Director, Roche Products (India) Pvt. Ltd., Rajwinder Mehdwan, in the presence of senior officials from both organizations.
Joint Secretary, DPIIT, Sanjiv highlighted the importance of industry–startup collaboration in integrating disruptive health innovations into the market. He noted that the partnership would offer guidance on regulatory pathways, intellectual property, and global health standards, along with opportunities for real-world validation. Capacity-building in Health Economics and Outcomes Research (HEOR), Good Clinical Practices (GCP), and patient engagement will also be a key focus area.
Managing Director, Roche Products (India) Pvt. Ltd., Rajwinder Mehdwan described the MoU as the beginning of a collaborative journey to support Indian healthtech startups in developing patient-centric solutions tailored to India’s healthcare needs.
